A Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease

About this Study

This study will evaluate the safety and effectiveness of inhaled treprostinil in participants with Pulmonary Hypertension (PH) due to Parenchymal Lung Disease.

Sponsor Protocol ID:RIN-PH-201
IRB Number:2017-0167
Closed for Enrollment
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria
  • Subject voluntarily gives informed consent to
    participate in the study. 
  • Males and females aged 18 years or older at the
    time of informed consent. 

Exclusion Criteria
  • Current use of any inhaled tobacco/marijuana products or a significant history of drug abuse at the time of informed consent. 
  •  Exacerbation of underlying lung disease or active
    pulmonary or upper respiratory infection within
    30 days of randomization. 
  • Initiation of pulmonary rehabilitation within 12 weeks prior to randomization. 
  • Severe concomitant illness limiting life expectancy
  • Acute pulmonary embolism within 90 days of
    randomization.

Categories Click category to view its trials.
Lungs/Breathing
Participating Locations
Pavilion - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Cathy Hudgins
Phone Number: 601-815-9276
Email: chudgins@umc.edu
Principal Investigator:Spurzem, John R
How to participate in our Clinical Trials